Allarity Therapeutics, Inc.
ALLR
$1.28
$0.032.40%
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -92.19% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -92.19% | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -92.19% | |||
| SG&A Expenses | -6.36% | -9.46% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -1.55% | -16.21% | |||
| Operating Income | 0.63% | 7.88% | |||
| Income Before Tax | -23.82% | 18.47% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -23.82% | 18.47% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -23.82% | 18.47% | |||
| EBIT | 0.63% | 7.88% | |||
| EBITDA | -- | -- | |||
| EPS Basic | -24.27% | 18.50% | |||
| Normalized Basic EPS | -24.35% | 18.48% | |||
| EPS Diluted | -24.27% | 18.50% | |||
| Normalized Diluted EPS | -24.35% | 18.48% | |||
| Average Basic Shares Outstanding | -0.36% | 0.02% | |||
| Average Diluted Shares Outstanding | -0.36% | 0.02% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||